Search clinical trials for: BMS-986001

Total 3173 results

Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

Heart Failure

United States
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Diabetes Mellitus Type 2

United States, Canada
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Mexico, Australia, Colombia, Chile, Peru
Bristol-Myers Squibb

Withdrawn

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Healthy
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Immunology

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Renal Failure | Congestive Heart Failure | Kidney Failure | Cardiac Failure | Myocardial Failure

Poland, Czechia
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Terminated

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects

Metabolics

United States
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Advanced Cancer

United States, Israel, Australia, Austria, Canada, Italy
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Bristol-Myers Squibb

Completed

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Healthy | Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States
Bristol-Myers Squibb

Completed

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (STANDUP AHF)

Heart Failure

France, Germany, Japan, Spain, United States, Argentina, Poland, Italy, Czechia, Greece, Netherlands, Canada, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

France, United States, Spain, Australia, Italy, Switzerland, United Kingdom
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Advanced Cancer

United States, Spain, France, Austria, Italy, Australia, Canada, Switzerland
Biohaven Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)

Neuromuscular Diseases | Spinal Muscular Atrophy | SMA

United States, Netherlands, United Kingdom, Spain, Czechia, Belgium, Germany, Italy, Poland
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Congestive Heart Failure | Liver Dysfunction | Heart Decompensation | Cardiac Failure | Liver Insufficiency | Myocardial Failure | Hepatic Failure

Hungary, Poland
Bristol-Myers Squibb
Clovis Oncology, Inc.

Completed

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (FRACTION-GC)

Advanced Gastric Cancer

United States, Israel, Netherlands, Canada, Italy, Australia, Germany, Singapore, Switzerland
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
Bristol-Myers Squibb

Withdrawn

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
Bristol-Myers Squibb

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Immunosuppression For Disease
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, Japan
Meridian Bioscience, Inc.
Bristol-Myers Squibb

Completed

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NASH - Nonalcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (FALCON 2)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD) | Hepatic Cirrhosis

United States, Japan
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

Healthy Participants

United States

3

Subscribe